Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing

BACKGROUND: Two ROS1 tyrosine kinase inhibitors have been approved for ROS1 fusion positive (ROS1+) non-small cell lung cancer (NSCLC) tumors. We performed a pan-tumor analysis of the incidence of ROS1 fusions to assess if more ROS1+ patients who could benefit from ROS1 TKIs could be identified. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagasaka, Misako, Zhang, Shannon S., Baca, Yasmine, Xiu, Joanne, Nieva, Jorge, Vanderwalde, Ari, Swensen, Jeffrey J., Spetzler, David, Korn, Wolfgang Michael, Raez, Luis E., Liu, Stephen V., Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585918/
https://www.ncbi.nlm.nih.gov/pubmed/37853341
http://dx.doi.org/10.1186/s12885-023-11457-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585918/
https://www.ncbi.nlm.nih.gov/pubmed/37853341
http://dx.doi.org/10.1186/s12885-023-11457-2

Ejemplares similares